

REFERENCES

1. Ahuja S, Brendle M, Smart L, Moore C, Thielking P, Robison R. (2022) Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study. *BMC Psychiatry*. Oct 3;22(1):634. doi: 10.1186/s12888-022-04268-5. PMID: 36192794; PMCID: PMC9528178.
2. Basso, L., Bonke, L., Aust, S., Gartner, M., Heuser-Collier, I., Otte, C., . . . Grimm, S. (2020). Antidepressant and neurocognitive effects of serial ketamine administration versus ECT in depressed patients. *J Psychiatr Res*, 123(1-8). <https://doi.org/10.1016/j.jpsychires.2020.01.002>
3. Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014). Acute antidepressant effects of intramuscular versus intravenous ketamine. *Indian J Psychol Med*, 36(1), 71-76. <https://doi.org/10.4103/0253-7176.127258> <https://doi.org/10.4103/0253-7176.127258>
4. Dames, S., Kryskow, P., & Watler, C. (2022). A cohort-based case report: The impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression. *Front. Psychiatry*, 12. <https://doi.org/10.3389/fpsy.2021.803279>
5. Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., . . . Wolfson, P. (2019). Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. *Journal of Psychoactive Drugs*, 51(2), 189-198. <https://doi.org/https://doi.org/10.1080/02791072.2019.1587556>
6. Drozd, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., Bhat, V., Diep, C., & Ladha, K. S. (2022) Ketamine-assisted psychotherapy: A systematic narrative review of the literature. *Journal of Pain Research*, 15, 1691-1706. 10.2147/JPR.S360733
7. Evans, J.W., Szczepanik, J., Brutsché, N., Park, L.T., Nugent, A.C., & Zarate, C.A. (2022). Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration. *Biol. Psychiatry* 84, 582–590. <https://dx.doi.org/10.1016/j.biopsych.2018.01.027>
8. Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C.J.A. (2018). Ketamine for the treatment of addiction: Evidence and potential mechanisms. *Neuropharmacology*, 142, 72–82. <https://doi.org/10.1016/j.neuropharm.2018.01.017>
9. Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., . . . Charney, D. S. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. *Am J Psychiatry*, 178(2), 193-202. <https://doi.org/10.1176/appi.ajp.2020.20050596>
10. Hasler, G. (2020). Toward specific ways to combine ketamine and psychotherapy in treating depression. *CNS Spectr*, 25(3), 445-447. <https://doi.org/10.1017/S1092852919001007>
11. Ionescu, D. F., Felicione, J. M., Gosai, A., Cusin, C., Shin, P., Shapero, B. G., & Deckersbach, T. (2018). Ketamine-associated brain changes: A review of the neuroimaging literature. *Harvard Review of Psychiatry*, 26(6), 320-339. doi:10.1097/HRP.000000000000179
12. Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018). Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. *Front Psychiatry*, 9, 277. <https://doi.org/10.3389/fpsy.2018.00277>
13. Khorramzadeh, E., & Lotfy, A. O. (1973). The use of ketamine in psychiatry. *Psychosomatics*, 14(6), 344- 346. [https://doi.org/10.1016/S0033-3182\(73\)71306-2](https://doi.org/10.1016/S0033-3182(73)71306-2)
14. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. *Can J Psychiatry*. 2016 Sep;61(9):540-60. doi: 10.1177/0706743716659417. Epub 2016 Aug 2. Erratum in: *Can J Psychiatry*. 2017 May;62(5):356. PMID: 27486148; PMCID: PMC4994790.

15. Kohtala, S. (2021). Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. *Pharmacol Rep*, 73(2), 323-345. <https://doi.org/10.1007/s43440-021-00232-4>
16. MacKay, M. A., Baker, G. B., & Dursun, S. M. (2020). Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. *Ther Adv Psychopharmacol*, 10, 2045125320916657. <https://doi.org/10.1177/2045125320916657>
17. Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D'Andrea, G., Collecchio, R., Di Muzio, I., Sensi, S.L., & Di Giannantonio, M. (2021). Therapeutic potentials of ketamine and esketamine in obsessive-compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): A review of the current literature. *Brain Sci.*, 11, 856. <https://doi.org/10.3390/brainsci11070856>
18. Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward synergies of ketamine and psychotherapy. *Front. Psychiatry*, 13. <https://doi.org/10.3389/fpsyg.2022.868103>
19. McInnes, L. A., Qian, J. J., Gargeya, R. S., DeBattista, C., & Heifets, B. D. (2022). A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. *J Affect Disord*, 301, 486-495. <https://doi.org/10.1016/j.jad.2021.12.097>
20. Muscat, S. A., Hartelius, G., Crouch, C. R., & Morin, K. W. (2021). An integrative approach to ketamine therapy may enhance multiple dimensions of efficacy: Improving therapeutic outcomes with treatment resistant depression. *Frontiers in Psychiatry*, 12. <https://doi.org/10.3389/fpsyg.2021.710338>
21. Nogo, D., Nazal, H., Song, Y., Teopiz, K. M., Ho, R., McIntyre, R. S., . . . Rosenblat, J. D. (2022). A review of potential neuropathological changes associated with ketamine. *Expert Opin Drug Saf*, 21(6), 813-831. <https://doi.org/10.1080/14740338.2022.2071867>
22. Swainson J, McGirr A, Blier P, Brietzke E, Richard-Devantoy S, Ravindran N, Blier J, Beaulieu S, Frey BN, Kennedy SH, McIntyre RS, Milev RV, Parikh SV, Schaffer A, Taylor VH, Tourjman V, van Ameringen M, Yatham LN, Ravindran AV, Lam RW. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: *Can J Psychiatry*. 2021 Feb;66(2):113-125. doi: 10.1177/0706743720970860. PMID: 33174760; PMCID: PMC7918868.
23. Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., O Reed, M., Jakubovski, E., & Bloch, M. H. (2018). Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial. *Neuropsychopharmacol.*, 43, 325–33. <https://doi.org/10.1038/npp.2017.194>
24. Tsang, V. W. L., Tao, B., Dames, S., Walsh, Z., & Kryskow, P. (2023). Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: A retrospective chart review. *Therapeutic Advances in Psychopharmacology*, <https://journals.sagepub.com/doi/10.1177/20451253231171512>
25. Tsang, V. W. L., Ragazan, D. C., Pamela Kryskow, P., Walsh, Z., & Dames, S. (2023) A pilot study comparing a community of practice program with and without concurrent ketamine-assisted therapy. *Journal of Psychoactive Drugs*. 10.1080/02791072.2023.2253798
26. Walsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., . . . Morgan, C. J. A. (2021). Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. *BJPsych Open*, 8(1), e19. <https://doi.org/10.1192/bjo.2021.1061>
27. Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate Jr., C. A., & Sanacora, G. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. *Am J Psychiatry*, 175, 150–8. <https://doi.org/10.1176/appi.ajp.2017.17040472>
28. Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., . . . Hawton, K. (2020). Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. *Aust N Z J Psychiatry*, 54(1), 29-45. <https://doi.org/10.1177/0004867419883341> World Health Organization.

29. Yermus, R., Verbora, M, Kennedy, S, McMaster, R., Kratina, S., Wolfson, E., Medrano, B., Bryson, N., Zaer, N., Bottos, J., Setlur, V., Lo, C. (2024) Ketamine-assisted psychotherapy provides lasting and effective results in the treatment of depression, anxiety and post-traumatic stress disorder at 3 and 6 months: Findings from a large single-arm retrospective effectiveness trial. *Psychedelic Medicine*. 23 January 2024 ahead of print. <https://doi.org/10.1101/2023.01.11.23284248>
30. Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. *Molecular Psychiatry*, 23(4), 801-811. doi:10.1038/mp.2017.255